Form 4: Sage Therapeutics Director Elizabeth Barrett Receives Stock Option Award

Director Elizabeth Barrett of Sage Therapeutics received a stock option award for 12,500 shares on June 10, 2024, according to a Form 4 filing.

Summary

• Elizabeth Barrett, a director at Sage Therapeutics, was granted a stock option to purchase 12,500 shares of common stock on June 10, 2024.
• The exercise price of the option is $10.90 per share.
• The options vest fully on the earlier of June 10, 2025, or the day before the 2025 Annual Meeting of Sage's stockholders, contingent upon continued service as a director.
• The stock option award was issued under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan, following the Non-Employee Director Compensation Program.
• A Power of Attorney was previously granted on May 20, 2024, authorizing certain individuals to act on Elizabeth Barrett's behalf for SEC filings.

Sentiment

Score: 7

Explanation: The document reflects a standard equity grant to a director, which is generally viewed positively as it aligns interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing her to contribute to the company's success.
• The vesting schedule encourages continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grant suggests an ongoing commitment to incentivizing board members.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain qualified board members and align their interests with those of shareholders. This grant is part of Sage Therapeutics' compensation program for non-employee directors.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice across the biotechnology industry.
• Companies like Biogen, Amgen, and Vertex Pharmaceuticals also utilize equity-based compensation to align director interests with shareholder value.
• The size of the grant (12,500 shares) and the vesting schedule (one year) appear to be within the typical range for director compensation packages in comparable companies.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders.
• The grant has a minimal impact on employees, customers, suppliers, and creditors.

Key Dates